Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 503

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 503
---
4. 2. The Audit Committee has discussed with representatives of Cherry Bekaert LLP, the independent public accounting firm, the matters which are required to be discussed with them under the provisions of Auditing Standard No. 61, as amended (Communications with Audit Committees). 3. The Audit Committee has discussed with Cherry Bekaert LLP, the independent public accounting firm, the auditors’ independence from management and TuHURA has received the written disclosures and the letter from the independent auditors required by applicable requirements of the Public Company Accounting Oversight Board. In addition, the Audit Committee considered whether the provision of non-audit services by Cherry Bekaert LLP, is compatible with maintaining its independence. In reliance on the reviews and discussions referred to above, the Audit Committee recommended to the TuHURA Board of Directors (and the TuHURA Board of Directors has approved) that the audited financial statements be included in TuHURA’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission. Audit Committee of TuHURA Biosciences, Inc. James Manuso, Ph.D Alan List, M.D. George Ng

| * | The foregoing report of the Audit Committee is not to be deemed “soliciting material” or deemed to be                                                                                                                                           
 “filed” with the Securities and Exchange Commission (irrespective of any general incorporation language in any document filed with the Securities and Exchange Commission) or subject to Regulation 14A of the Securities Exchange Act of 1934, 
 as amended, or to the liabilities of Section 18 of the Securities Exchange Act of 1934, except to the extent we specifically incorporate it by reference into a document filed with the Securities and Exchange Commission.                     |

Compensation Committee The compensation committee assists the TuHURA Board of Directors in fulfilling its oversight responsibilities relating to (i) corporate governance practices and policies and (ii) compensation matters, including compensation of the directors and senior management of TuHURA and the administration of compensation plans of TuHURA. The compensation committee of TuHURA consists of Alan List, M.D. (chairman) and James Manuso, Ph.D., MBA. Each member of TuHURA’s compensation committee is a “non-employee” director within the meaning of Rule 16b-3 of the rules promulgated under the Exchange Act and independent within the meaning of the independent director guidelines of Nasdaq. 321

Nominating and Corporate Governance